Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) – Research analysts at Leerink Partnrs lowered their FY2026 EPS estimates for shares of Xenon Pharmaceuticals in a report released on Tuesday, October 15th. Leerink Partnrs analyst M. Goodman now forecasts that the biopharmaceutical company will post earnings per share of ($3.54) for the year, down from their previous estimate of ($3.40). The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share.
Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.05). During the same period last year, the business earned ($0.72) earnings per share.
Read Our Latest Research Report on XENE
Xenon Pharmaceuticals Trading Up 1.6 %
Xenon Pharmaceuticals stock opened at $43.31 on Friday. The firm has a market capitalization of $3.27 billion, a P/E ratio of -15.98 and a beta of 1.25. The business has a 50-day moving average of $39.90 and a 200-day moving average of $40.16. Xenon Pharmaceuticals has a 1 year low of $27.99 and a 1 year high of $50.99.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the stock. Blue Trust Inc. raised its stake in shares of Xenon Pharmaceuticals by 174.7% during the 3rd quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 641 shares in the last quarter. nVerses Capital LLC acquired a new position in Xenon Pharmaceuticals during the third quarter worth $102,000. Handelsbanken Fonder AB raised its position in Xenon Pharmaceuticals by 8.1% during the third quarter. Handelsbanken Fonder AB now owns 22,700 shares of the biopharmaceutical company’s stock worth $894,000 after acquiring an additional 1,700 shares in the last quarter. Point72 Asset Management L.P. raised its position in Xenon Pharmaceuticals by 74.7% during the second quarter. Point72 Asset Management L.P. now owns 482,022 shares of the biopharmaceutical company’s stock worth $18,794,000 after acquiring an additional 206,163 shares in the last quarter. Finally, Quarry LP lifted its stake in Xenon Pharmaceuticals by 207.7% in the second quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company’s stock valued at $156,000 after acquiring an additional 2,700 shares during the last quarter. 95.45% of the stock is owned by institutional investors and hedge funds.
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
See Also
- Five stocks we like better than Xenon Pharmaceuticals
- Canadian Penny Stocks: Can They Make You Rich?
- Global Lithium Demand Soars: Top 3 Stocks Positioned to Gain
- What Are Dividend Achievers? An Introduction
- Oil Prices Fall, Sector Pulls Back: Time to Buy this Stock?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- AI Boom Fuels Demand for Dominion Energy Stock
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.